

National Board of Examinations

Question Paper Name :	DrNB GYNAECOLOGICAL ONCOLOGY Paper3
Subject Name :	DrNB GYNAECOLOGICAL ONCOLOGY Paper3
Creation Date :	2022-06-25 17:21:06
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB GYNAECOLOGICAL ONCOLOGY Paper3

Group Number :	1
Group Id :	3271871282
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Break time :	0
Group Marks :	100
Is this Group for Examiner? :	No
Examiner permission :	Cant View
Show Progress Bar? :	No

DrNB GYNAECOLOGICAL ONCOLOGY Paper3

Section Id :	3271871285
---------------------	------------

Section Number : 1
Section type : Offline
Mandatory or Optional : Mandatory
Number of Questions to be attempted : 10
Section Marks : 100
Enable Mark as Answered Mark for Review and Clear Response : Yes
Maximum Instruction Time : 0
Sub-Section Number : 1
Sub-Section Id : 3271871289
Question Shuffling Allowed : No

Question Number : 1 Question Id : 32718711872 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors in ovarian cancer:

- Synthetic lethality. [3]
- Evidence for frontline management of ovarian cancer. [4]
- Toxicity of PARPi in ovarian cancer patients. [3]

Question Number : 2 Question Id : 32718711873 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Management of locally advanced cervical cancer:

- Describe standard techniques and doses of radiotherapy. [6]

b) Describe the mechanism and therapeutic synergism of concurrent chemotherapy. [4]

Question Number : 3 Question Id : 32718711874 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Clinical research methodology:

a) What are various Phases of clinical trials? [5]

b) Describe design of a phase-III randomized trial to test non-inferiority of oral metronomic chemotherapy compare to conventional intravenous chemotherapy in recurrent epithelial ovarian cancer. [5]

Question Number : 4 Question Id : 32718711875 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Describe risk-stratification and adjuvant treatment protocols for endometrial cancer. [10]

Question Number : 5 Question Id : 32718711876 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Briefly describe the following with regards to gynecological cancer management:

a) Image-guided radiation therapy (IGRT). [5]

b) Intensity-modulated radiation therapy (IMRT). [5]

Question Number : 6 Question Id : 32718711877 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Quality of Life:

a) Describe Patient Reported Outcome (PRO) measures and tools. [5]

b) Briefly describe the instruments used for the assessment of health related quality of life in cervical cancer patients. [5]

Question Number : 7 Question Id : 32718711878 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Palliative care:

- a) What is end of life care in cancer patients? [5]
- b) Briefly describe management of bowel obstruction in a platinum-resistant recurrent ovarian cancer patient. [5]

Question Number : 8 Question Id : 32718711879 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Alkylating agents:

- a) Commonly used alkylating agents in gynecological oncology [2]
- b) Mechanism of action [3]
- c) Indications [3]
- d) Enumerate side effects [2]

Question Number : 9 Question Id : 32718711880 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

- a) What are the indications for adjuvant radiotherapy in carcinoma vulva? [5]
- b) Common long term adverse effects of surgery and adjuvant RT in such patients. [5]

Question Number : 10 Question Id : 32718711881 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Immunotherapy:

- a) Basis of cancer immunotherapy. [3]
- b) Role in endometrial cancer. [4]
- c) Enumerate common toxicities. [3]

